Genexine Establishes Dual CEO System with Sung Young-chul and Woo Jung-won

"Vaccine and Major Pipeline Development Speed"

[Asia Economy Reporter Kim Ji-hee] On the 29th, Genexine held the 22nd regular general meeting of shareholders and a board meeting at its headquarters, appointing Chairman Sung Young-chul and President Woo Jung-won as co-CEOs, and announced that it will operate under a dual CEO system.

Newly appointed CEO Woo Jung-won has served as Head of Clinical Development, Head of Business Development, and Director of the Protein Production Technology Research Institute at Genexine since 2013. He was appointed president earlier this year and is leading the company overall.

At the same shareholders' meeting, Vice President Hong Sung-joon was appointed as an inside director, Neil Wama, head of the U.S. branch of iMap Biopharma, was appointed as an outside director, and Kim Young-jin, chairman of Handok, was appointed as a non-executive director.

Hong Sung-joon, appointed as an inside director, joined Genexine last year as Chief Financial Officer (CFO) and Chief Operating Officer (COO). Neil Wama, appointed as an outside director, previously worked at Novartis and served as CEO of Byron Therapeutics and CEO of Opexa Therapeutics. He is a bio-healthcare expert who joined iMap as head of its U.S. branch in 2019.

Genexine stated, "Through the dual CEO system, faster business execution will be possible, accelerating the development of COVID-19 vaccines and important pipelines."

This content was produced with the assistance of AI translation services.